Search research articles
Contact Us
Filters
Showing results (31-40 of 145) with videos related to
Page
of 15
Sort By:
Haematologica
|
December 1, 2022
The present and future of measurable residual disease testing in acute myeloid leukemia
James S Blachly, Roland B Walter, Christopher S Hourigan
Blood
|
February 9, 2023
How I treat AML incorporating the updated classifications and guidelines
Firas El Chaer, Christopher S Hourigan, Amer M Zeidan
Leukemia
|
December 16, 2018
Refining AML outcome prediction
Christopher S Hourigan, Robert Peter Gale, Roland B Walter
Journal of Leukemia (Los Angeles, Calif.)
|
September 23, 2014
Adult Acute Myeloid Leukemia Long-term Survivors
M Jennifer Cheng, Christopher S Hourigan, Thomas J Smith
Best Practice & Research. Clinical Haematology
|
June 23, 2023
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia
Zoë C Wong, Laura W Dillon, Christopher S Hourigan
Blood Reviews
|
February 14, 2017
Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia
Mary-Elizabeth Percival, Catherine Lai, Elihu Estey, et al.
Expert Review of Hematology
|
June 24, 2017
Immunological effects of hypomethylating agents
Katherine E Lindblad, Meghali Goswami, Christopher S Hourigan, et al.
Seminars in Hematology
|
June 27, 2015
Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia
Peter Hokland, Hans B Ommen, Matthew P Mulé, et al.
Bone Marrow Transplantation
|
November 1, 2019
Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation
Megan Othus, Robert Peter Gale, Christopher S Hourigan, et al.
Journal of Clinical Medicine
|
September 20, 2017
Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
Gregory W Roloff, Catherine Lai, Christopher S Hourigan, et al.
Page
of 15
Search research articles
Search
Showing results (31-40 of 145) with videos related to
Sort By:
Page
of 15
Haematologica
|
December 1, 2022
The present and future of measurable residual disease testing in acute myeloid leukemia
James S Blachly, Roland B Walter, Christopher S Hourigan
Blood
|
February 9, 2023
How I treat AML incorporating the updated classifications and guidelines
Firas El Chaer, Christopher S Hourigan, Amer M Zeidan
Leukemia
|
December 16, 2018
Refining AML outcome prediction
Christopher S Hourigan, Robert Peter Gale, Roland B Walter
Journal of Leukemia (Los Angeles, Calif.)
|
September 23, 2014
Adult Acute Myeloid Leukemia Long-term Survivors
M Jennifer Cheng, Christopher S Hourigan, Thomas J Smith
Best Practice & Research. Clinical Haematology
|
June 23, 2023
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia
Zoë C Wong, Laura W Dillon, Christopher S Hourigan
Blood Reviews
|
February 14, 2017
Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia
Mary-Elizabeth Percival, Catherine Lai, Elihu Estey, et al.
Expert Review of Hematology
|
June 24, 2017
Immunological effects of hypomethylating agents
Katherine E Lindblad, Meghali Goswami, Christopher S Hourigan, et al.
Seminars in Hematology
|
June 27, 2015
Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia
Peter Hokland, Hans B Ommen, Matthew P Mulé, et al.
Bone Marrow Transplantation
|
November 1, 2019
Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation
Megan Othus, Robert Peter Gale, Christopher S Hourigan, et al.
Journal of Clinical Medicine
|
September 20, 2017
Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
Gregory W Roloff, Catherine Lai, Christopher S Hourigan, et al.
Page
of 15